Efficacy and Safety Evaluation of Different Lebrikizumab Dosages in Atopic Dermatitis Patients Over 16 to 24 Weeks: A BIOREP Registry Analysis.

Rob F, Kojanová M, Hercogová JT, Baláž M, Horažďovský J, Vantuchová Y, Jandová M, Hrazdírová K, Nečas M, Stuchlík D, Říčař J, Antal Z, Gkalpakiotis S

Open source

DOI: 10.1111/ijd.70180
Published: 2026 May
Container: International journal of dermatology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1111/ijd.70180,
  title = {Efficacy and Safety Evaluation of Different Lebrikizumab Dosages in Atopic Dermatitis Patients Over 16 to 24 Weeks: A BIOREP Registry Analysis.},
  author = {Rob F and Kojanová M and Hercogová JT and Baláž M and Horažďovský J and Vantuchová Y and Jandová M and Hrazdírová K and Nečas M and Stuchlík D and Říčař J and Antal Z and Gkalpakiotis S},
  year = {2026},
  journal = {International journal of dermatology},
  doi = {10.1111/ijd.70180},
  url = {https://doi.org/10.1111/ijd.70180}
}

RIS

TY  - JOUR
TI  - Efficacy and Safety Evaluation of Different Lebrikizumab Dosages in Atopic Dermatitis Patients Over 16 to 24 Weeks: A BIOREP Registry Analysis.
AU  - Rob F
AU  - Kojanová M
AU  - Hercogová JT
AU  - Baláž M
AU  - Horažďovský J
AU  - Vantuchová Y
AU  - Jandová M
AU  - Hrazdírová K
AU  - Nečas M
AU  - Stuchlík D
AU  - Říčař J
AU  - Antal Z
AU  - Gkalpakiotis S
PY  - 2026
JO  - International journal of dermatology
DO  - 10.1111/ijd.70180
UR  - https://doi.org/10.1111/ijd.70180
ER  -

APA

F, R., M, K., JT, H., M, B., J, H., Y, V., M, J., K, H., M, N., D, S., J, Ř., Z, A., & S, G. (2026). Efficacy and Safety Evaluation of Different Lebrikizumab Dosages in Atopic Dermatitis Patients Over 16 to 24 Weeks: A BIOREP Registry Analysis.. International journal of dermatology. https://doi.org/10.1111/ijd.70180

Source records

pubmed · retrieved 2026-09-26T08:52:07.437Z